AqueSys, Inc., an Irvine, California-based medical device company that develops, manufactures and distributes proprietary implants for glaucoma, has secured $35m in Series C financing.
The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.
The AqueSys implant offers a 10-minute non invasive surgical treatment to halt glaucoma-related vision loss.
According to Ron Bache, AqueSys, Inc. President and CEO, the company is now well capitalized to achieve its clinical, regulatory and commercial goals.
FinSMEs
29/06/2010